3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
Temozolomide
4
Irinotecan
4
eribulin
2
Topotecan
2
LY2940680
2
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
surufatinib
1
sonidegib
1
soblidotin
1
ribociclib
1
regorafenib
1
pegfilgrastim
1
palbociclib
1
omburtamab I-131
1
lenvatinib
1
iso-sulfan blue
1
dostarlimab
1
dinutuximab
1
copanlisib
1
cixutumumab
1
ceritinib
1
bempegaldesleukin
1
amino-acid, glucose, and electrolyte solution
1
abemaciclib
1
Vincristine
1
Pemetrexed
1
Nivolumab
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gemcitabine
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Rhabdomyosarcoma
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled